Posted by Michael Wonder on 29 Sep 2016
More on NICE recommendation of Imlygic
28 September 2016 - More on NICE's guidance on the use of talimogene laherparepvec for unresectable metastatic melanoma.
On September 28, NICE published guidance that recommended talimogene laherparepvec as an option for the treatment of regionally or distantly metastatic (stage IIIB, IIIC, or IVM1a) melanoma that has not spread to bone, brain, lung, or other internal organs.
Talimogene laherparepvec was only recommended if systemically administered immunotherapies are not suitable and if Amgen provides it with the discount agreed in the patient access scheme.
